HS-110

HS-110 for the Treatment of Non-small Cell Lung Cancer

HS-110 (viagenpumatucel-L) is our first biologic product candidate in a series of proprietary ImPACT® based immunotherapies designed to stimulate a patient’s own T-cells to destroy cancer.

Program Mechanism of Action
(Modality)
Indication Preclinical Phase 1 Phase 2 Phase 3

HS-110

gp96 + CTAs
(Cell Therapy)
NSCLC
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

CTA = Cancer testis antigens; NSCLC = Non-small cell lung cancer

Designed to Secrete a Wide Range of Cancer Testis Antigens

Using our gp96 platform, the company has developed HS-110 as a treatment for patients with non-small cell lung cancer.

HS-110 is an off-the-shelf cell-based therapy. Our scientists have genetically engineered HS-110 to secrete a wide range of cancer testis antigens chaperoned by gp96 proteins.

In clinical trials, HS-110 demonstrated a broad activation of T-cell mediated immune response in cancer patients.

HS-110 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

Our HS-110 Phase 2, multicenter clinical trial is evaluating the safety and efficacy of HS-110 in combination with Bristol-Myers Squibb’s checkpoint inhibitor, nivolumab (Opdivo®) or Merck’s checkpoint inhibitor, pembrolizumab (Keytruda®). The enrollment for this trial has completed with approximately 120 patients.

Positive interim results have been presented at leading medical conferences including American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR) and Society for Immunotherapy of Cancer (SITC).

Visit www.clinicaltrials.gov for more details.

A Clinical Study of HS-110 in Combination with Multiple Treatment Regimens in Patients with Non-Small Cell Lung Cancer

pipeline VISIT WWW.CLINICALTRIALS.GOV FOR MORE DETAILS

HS-110 Product Manufacturing

The HS-110 product used in our clinical trials is manufactured under cGMP guidelines. The cell line is grown in large quantities, dispensed into individual doses, frozen in liquid nitrogen, irradiated to render cell replication incompetent and quality tested in compliance with FDA guidelines.